However, we reached the opposite result to a previous study, in which elesclomol could directly target FDX1 and promote copper-induced cell death in human rhabdomyosarcoma and LUAD cells (Tsvetkov et al., 2022). The gene discussed is FDX1; the disease is rhabdomyosarcoma.